Loading organizations...
§ Venture Capital · London, United Kingdom
Global venture capital company that invests in and builds breakthrough biotech companies focused on life sciences innovations.
Arix Bioscience is a global venture capital firm based in London, England, that invests in and builds clinical-stage biotechnology companies focused on novel therapeutics. Prior to its acquisition and subsequent delisting from the London Stock Exchange in February 2024, the firm managed an estimated net asset value of approximately £255 million. The organization generates financial returns by financing life sciences businesses through their clinical development phases, ultimately targeting capital appreciation via initial public offerings or corporate acquisitions. The firm has received backing from corporate investors such as Takeda Ventures, and was ultimately acquired by RTW Investments in an all-share transaction. Its historical investment portfolio features prominent biopharmaceutical developers, including clinical-stage biotech companies like Autolus, Harpoon Therapeutics, and Aura Biosciences. Arix Bioscience was founded in 2015 by Sir Christopher Evans, Joe Anderson, and Jonathan Peacock.
Key people at Arix Bioscience.
Arix Bioscience is a global venture capital firm specializing in investing in and building breakthrough biotech companies focused on cutting-edge advances in life sciences. Its mission is to accelerate the development of innovative healthcare solutions by providing capital, expertise, and global networks to exceptional entrepreneurs in the biotech sector. The firm primarily invests in early-stage and growth-stage companies within biotechnology and healthcare, aiming to transform scientific advances into important new treatments for patients. By being a publicly listed company, Arix broadens access to this high-growth sector for a wider range of investors, thereby impacting the startup ecosystem by fueling innovation and job creation in life sciences[1][2][3][5].
Founded in 2016 and based in London, Arix Bioscience evolved from earlier life sciences investment initiatives, including a fund managed by Arthurian Life Sciences and supported by the Welsh Government. Key figures include Sir Chris Evans, a life sciences serial investor who chaired the predecessor fund. Over time, Arix has refined its focus on biotech ventures that span all stages of growth—from seed and preclinical to clinical and late-stage assets—leveraging its deep sector expertise and capital market experience to support startups and scale-ups in the life sciences ecosystem[2][3][6].
Arix Bioscience rides the wave of rapid advancements in biotechnology and life sciences, a sector driven by increasing demand for novel therapies and precision medicine. The timing is favorable due to breakthroughs in genomics, immunotherapy, and digital health, alongside growing investor interest in healthcare innovation. By bridging capital and expertise, Arix influences the broader ecosystem by enabling startups to overcome funding and development hurdles, thus accelerating the translation of scientific research into patient-impacting solutions[1][3].
Looking ahead, Arix Bioscience is positioned to capitalize on emerging biotech trends such as gene editing, cell therapies, and AI-driven drug discovery. Its public listing provides a platform for sustained capital raising and portfolio diversification. As the biotech sector continues to expand globally, Arix’s influence is likely to grow, further shaping the innovation landscape by supporting transformative healthcare technologies and expanding access to cutting-edge treatments. This trajectory ties back to its core mission of turning breakthrough science into meaningful patient outcomes[1][3][5].
Key people at Arix Bioscience.
